The abstract is read at the publisher; the summary is JClub's.
Saroglitazar 0.97 mg improved biochemical response in 148 patients with primary biliary cholangitis at week 52, reaching 56.7% versus 9.8% with placebo.
- Why it matters: Patients with primary biliary cholangitis who respond inadequately or cannot tolerate UDCA need better options, and prior phase 2a results required confirmation in a larger trial.
- What they did: EPICS-III was a phase 2b/3 adaptive, double-blind randomized controlled trial; phase 3 assigned 97 to saroglitazar and 51 to placebo for 52 weeks, using ALP and bilirubin criteria for response.
- The result: ALP normalization occurred in 8.2% with saroglitazar versus 0% with placebo (p=0.016), with adverse events reported in 81.1% versus 90.5% over 52 weeks.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.